Abeona Therapeutics' (ABEO) Overweight Rating Reaffirmed at Cantor Fitzgerald

Cantor Fitzgerald reaffirmed their overweight rating on shares of Abeona Therapeutics (NASDAQ:ABEO - Free Report) in a research note published on Tuesday, Benzinga reports. They currently have a $36.00 target price on the biopharmaceutical company's stock.

Separately, StockNews.com lowered shares of Abeona Therapeutics from a hold rating to a sell rating in a research note on Tuesday.

Abeona Therapeutics Stock Down 53.7 %

Shares of NASDAQ ABEO traded down $3.95 during trading hours on Tuesday, hitting $3.41. 5,495,310 shares of the stock were exchanged, compared to its average volume of 400,321. The company has a market cap of $93.26 million, a PE ratio of -1.32 and a beta of 1.49. The firm has a fifty day moving average price of $7.49 and a 200-day moving average price of $5.65. Abeona Therapeutics has a 12 month low of $2.83 and a 12 month high of $9.01.

Abeona Therapeutics (NASDAQ:ABEO - Get Free Report) last posted its quarterly earnings data on Monday, March 18th. The biopharmaceutical company reported ($0.64) EPS for the quarter, missing the consensus estimate of ($0.51) by ($0.13). As a group, equities analysts anticipate that Abeona Therapeutics will post -1.83 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Abeona Therapeutics

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Citigroup Inc. lifted its stake in shares of Abeona Therapeutics by 125.0% in the third quarter. Citigroup Inc. now owns 450,000 shares of the biopharmaceutical company's stock worth $1,894,000 after buying an additional 250,000 shares in the last quarter. Schonfeld Strategic Advisors LLC purchased a new position in shares of Abeona Therapeutics in the third quarter worth about $648,000. Worth Venture Partners LLC lifted its stake in shares of Abeona Therapeutics by 76.6% in the third quarter. Worth Venture Partners LLC now owns 281,280 shares of the biopharmaceutical company's stock worth $1,184,000 after buying an additional 121,969 shares in the last quarter. AIGH Capital Management LLC lifted its stake in shares of Abeona Therapeutics by 77.7% in the third quarter. AIGH Capital Management LLC now owns 1,135,252 shares of the biopharmaceutical company's stock worth $4,779,000 after buying an additional 496,278 shares in the last quarter. Finally, Barclays PLC lifted its stake in shares of Abeona Therapeutics by 100.0% in the third quarter. Barclays PLC now owns 371,276 shares of the biopharmaceutical company's stock worth $1,564,000 after buying an additional 185,638 shares in the last quarter. 80.56% of the stock is owned by hedge funds and other institutional investors.

Abeona Therapeutics Company Profile

Abeona Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on developing and delivering gene therapy products for severe and life-threatening rare diseases. The company's lead programs are EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB); ABO-102, which are AAV based gene therapies for Sanfilippo syndrome type A; and ABO-101, an adeno-associated virus (AAV) based gene therapies for Sanfilippo syndrome type B.